Eisai Presents Latest Lemborexant Data at World Sleep 2019, Highlighting Long-Term Efficacy and Safety in Insomnia and Potential in ISWRD

TOKYO, Oct. 15, 2019 /PRNewswire/ -- At the World Sleep 2019 congress, held in Vancouver, Canada, from September 20 to 25, 2019, Eisai Co., Ltd. (Headquarters: Tokyo; CEO: Haruo Naito) presented the latest data on lemborexant, which is currently under development. Lemborexant is an investigational sleep-wake regulator being developed for the treatment of various sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD).

At this conference, oral presentations were delivered covering the following topics: the first-ever release of analysis results from a 12-month dosing period in the Phase III clinical trial (SUNRISE-2 trial) of lemborexant, which aimed to evaluate the efficacy and safety of long-term administration in patients with insomnia; and the impact of lemborexant on sleep architecture in elderly patients with insomnia in the Phase III clinical trial (SUNRISE-1 trial) evaluating efficacy and safety. Additionally, regarding non-clinical studies, Eisai presented an oral report on the evaluation of lemborexant’s efficacy using ISWRD model mice. Six poster themes were displayed, including partial analysis results from the SUNRISE-2 trial, such as the anti-fatigue efficacy of lemborexant assessed by patient-reported outcomes during the 6-month placebo-controlled dosing period.

Lemborexant acts on the orexin neurotransmitter system,KotongPastRegulate the sleep-wake rhythm to promote sleep onset, maintain sleep, and facilitate awakening.

Lemborexant, currently under development, will be used to treat sleep-wake disorders, including insomnia. Eisai has alreadyIn the United States(December 2018), Japan (March 2019), Canada (August of the same year) conducted new drugXuApplication is permissible.In addition, a Phase II clinical trial targeting ISWRD caused by mild to moderate Alzheimer’s disease dementia is also ongoing. For details on the ongoing clinical trials, please visitclinicaltrials.gov。

Through the development of lemborexant, Eisai is committed to bringing benefits to patients with sleep-wake disorders, including those with insomnia.GoFacilitate rapid sleep onset and high-quality sleep, enabling patients to enjoy vibrant daytime lives and contribute to their return to work/recovery. Furthermore, contribute to addressing unmet medical needs and enhancing the well-being of patients and their families.